Sage Journals: Discover world-class research

Abstract

Background:

We explored the evolution of brain atrophy in relation to development of confirmed disability progression (CDP) on serial 1.5T magnetic resonance imaging (MRI) scans over a 10-year period in 181 patients with early relapsing–remitting multiple sclerosis (RRMS).

Methods:

At 10-year follow-up, they were divided into those with (100) or without (76) CDP (confirmed after 48 weeks). Changes in whole brain (WB), cortical, gray matter (GM), white matter, and ventricular cerebrospinal fluid (vCSF) volumes were calculated on three-dimensional T1-weighted (3D-T1) scans between all available time points.

Results:

In multiple sclerosis (MS) patients with CDP compared to those without, the greatest effect size percentage volume change from baseline to follow-up was detected for WB (d = 0.55, −7.5% vs −5.2%, p < 0.001), followed by vCSF (d = 0.51, +41.1% vs +25.7%, p < 0.001), cortical (d = 0.49, −7.7% vs −6.2%, p = 0.001), and GM (d = 0.40, −7.1% vs −5.8%, p = 0.006) volumes. Mixed-effects model analysis, adjusted for age, sex, and treatment change, showed significant interactions between CDP status and percentage changes for WB and vCSF (p < 0.001), cortical (p = 0.02), and GM (p = 0.04) volumes.

Conclusions:

WB and cortical atrophy, and enlargement of vCSF spaces are associated with development of CDP on serial yearly MRI assessments over a period of 10 years.

Keywords

Multiple sclerosis MRI brain atrophy disability progression whole brain ventricular cerebrospinal fluid volume

Get full access to this article

View all access options for this article.

References

Frohman

Racke

Raine

. Multiple sclerosis—The plaque and its pathogenesis. N Engl J Med 2006; 354: 942–955.

Zivadinov

Reder

Filippi

. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008; 71: 136–144.

Bermel

Bakshi

. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 2006; 5: 158–170.

Miller

Barkhof

Frank

. Measurement of atrophy in multiple sclerosis: Pathological basis, methodological aspects and clinical relevance. Brain 2002; 125: 1676–1695.

Minagar

Barnett

Benedict

. The thalamus and multiple sclerosis: Modern views on pathologic, imaging, and clinical aspects. Neurology 2013; 80: 210–219.

De Stefano

Giorgio

Battaglini

. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010; 74: 1868–1876.

Fisher

Lee

Nakamura

. Gray matter atrophy in multiple sclerosis: A longitudinal study. Ann Neurol 2008; 64: 255–265.

Jacobsen

Hagemeier

Myhr

. Brain atrophy and disability progression in multiple sclerosis patients: A 10-year follow-up study. J Neurol Neurosurg Psychiatry 2014; 85:1109–1115.

Popescu

Agosta

Hulst

. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 2013; 84: 1082–1091.

10.

Uher

Blahova-Dusankova

Horakova

. Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. J Neurol 2014; 261: 1735–1744.

11.

Calabrese

Reynolds

Magliozzi

. Regional distribution and evolution of gray matter damage in different populations of multiple sclerosis patients. PLoS ONE 2015; 10: e0135428.

12.

Horakova

Cox

Havrdova

. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: A case-control study. J Neurol Neurosurg Psychiatry 2008; 79: 407–414.

13.

Horakova

Dwyer

Havrdova

. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: A 5-year longitudinal study. J Neurol Sci 2009; 282: 112–119.

14.

Zivadinov

Bergsland

Dolezal

. Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years. AJNR Am J Neuroradiol 2013; 34: 1931–1939.

15.

De Stefano

Airas

Grigoriadis

. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 2014; 28: 147–156.

16.

Calabrese

Rinaldi

Mattisi

. The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 2011; 77: 257–263.

17.

Zivadinov

Havrdova

Bergsland

. Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology 2013; 268: 831–841.

18.

Rocca

Mesaros

Pagani

. Thalamic damage and long-term progression of disability in multiple sclerosis. Radiology 2010; 257: 463–469.

19.

Khaleeli

Ciccarelli

Manfredonia

. Predicting progression in primary progressive multiple sclerosis: A 10-year multicenter study. Ann Neurol 2008; 63: 790–793.

20.

Havrdova

Zivadinov

Krasensky

. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult Scler 2009; 15: 965–976.

21.

Zivadinov

Tekwe

Bergsland

. Bimonthly evolution of cortical atrophy in early relapsing-remitting multiple sclerosis over 2 years: A longitudinal study. Mult Scler Int 2013; 2013: 231345.

22.

Benedict

Bruce

Dwyer

. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol 2006; 63: 1301–1306.

23.

Kalincik

Vaneckova

Tyblova

. Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: A longitudinal cohort study. PLoS ONE 2012; 7: e50101.

24.

Uher

Horakova

Kalincik

. Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon beta-1a. Eur J Neurol 2015; 22: 1113–1123.

25.

Kalkers

Ameziane

Bot

. Longitudinal brain volume measurement in multiple sclerosis: Rate of brain atrophy is independent of the disease subtype. Arch Neurol 2002; 59: 1572–1576.

26.

Pagani

Rocca

Gallo

. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. AJNR Am J Neuroradiol 2005; 26: 341–346.

27.

Dwyer

Bergsland

Zivadinov

. Improved longitudinal gray and white matter atrophy assessment via application of a 4-dimensional hidden Markov random field model. Neuroimage 2014; 90: 207–217.

28.

Smith

Zhang

Jenkinson

. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002; 17: 479–489.

29.

Zivadinov

Heininen-Brown

Schirda

. Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: A case-control study. Neuroimage 2012; 59: 331–339.

30.

Zivadinov

Rudick

De Masi

. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57: 1239–1247.

31.

De Stefano

Stromillo

Giorgio

. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016; 87: 93–99.

32.

Sumowski

Rocca

Leavitt

. Brain reserve and cognitive reserve protect against cognitive decline over 4.5 years in MS. Neurology 2014; 82: 1776–1783.

33.

Amato

Razzolini

Goretti

. Cognitive reserve and cortical atrophy in multiple sclerosis: A longitudinal study. Neurology 2013; 80: 1728–1733.

34.

Enzinger

Fuchs

Pichler

. Predicting the severity of relapsing-remitting MS: The contribution of cross-sectional and short-term follow-up MRI data. Mult Scler 2011; 17: 695–701.

35.

Minneboo

Uitdehaag

Jongen

. Association between MRI parameters and the MS severity scale: A 12 year follow-up study. Mult Scler 2009; 15: 632–637.

36.

Jehna

Pirpamer

Khalil

. Periventricular lesions correlate with cortical thinning in multiple sclerosis. Ann Neurol 2015; 78: 530–539.

37.

Liu

Pardini

Yaldizli

. Magnetization transfer ratio measures in normal-appearing white matter show periventricular gradient abnormalities in multiple sclerosis. Brain 2015; 138: 1239–1246.

38.

Wattjes

Rovira

Miller

. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—Establishing disease prognosis and monitoring patients. Nat Rev Neurol 2015; 11: 597–606.

39.

Bermel

You

Foulds

. Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann Neurol 2013; 73: 95–103.

40.

Ford

Johnson

Lisak

. A prospective open-label study of glatiramer acetate: Over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006; 12: 309–320.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.32 MB

0.17 MB

0.13 MB

0.15 MB

A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients

Abstract

Background:

Methods:

Results:

Conclusions:

Keywords

Get full access to this article

References

Supplementary Material